Evaluation of the PROMETA Treatment Program for treatment of alcohol dependence at Cedars-Sinai Medical Center, Los Angeles, CA
• Jeffrey Wilkins, MD; Vice Chairman, Department of Psychiatry and Mental Health • 80-subject, randomized, double-blind, placebo-controlled study of the Prometa Treatment Program on neurocognitive function and cravings in alcohol dependence.
• First subject in: April 2007
Clinical study of the PROMETA Treatment Program for alcohol dependence at Institute of Addiction Medicine in Philadelphia, PA
• Jenny Starosta, PhD and Joseph Volpicelli, MD • 120-subject, randomized, double-blind, placebo-controlled study; changes in neurocognitive functioning, reduced cravings, subject retention, self-report and biomarkers of alcohol use, safety and efficacy as endpoints
• First subject in: March 2007
Clinical study for testing efficacy for treatment of methamphetamine dependence at UCLA’s Integrated Substance Abuse Program (ISAP), Los Angeles, CA
• Walter Ling, MD; board-certified neurologist and psychiatrist • 120-subject, multi-site, randomized, double-blind, placebo-controlled study; abstinence and preventing relapse as endpoints
